Stem Cell Therapy for Limbal Stem Cell Deficiency
This is a phase I open-label clinical study to determine the safety and feasibility of limbal stem cell therapy in patients that have been diagnosed with severe limbal stem cell deficiency. We will investigate the ability to manufacture and transplant the patient’s own stem cells onto the cornea and evaluate their ability to regenerate the ocular surface without serious adverse events.
- Male or female ≥18 years of age.
- Best corrected visual acuity in the affected eye is 20/160 or less. The other eye does not have LSCD.
- Both eyes have the disease
- The cause of the stem cell deficiency is due to genetic or autoimmune disease.
For any questions, please contact the research team: [email protected]
Investigator: Sophie X. Deng, MD, PhD
Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation
This is a prospective, randomized, vehicle-controlled clinical trial evaluating corneal collagen cross-linking the keratoprothesis carrier tissue in subjects who are candidates for high-risk keratoprosthesis implantation because of a history of corneal melts, sterile corneal ulcers, or autoimmune diseases.
Investigators: Anthony J. Aldave, MD, and Sophie X. Deng, MD, PhD